Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
World J Clin Cases ; 11(36): 8447-8457, 2023 Dec 26.
Article in English | MEDLINE | ID: mdl-38188218

ABSTRACT

BACKGROUND: The purpose of the present study was to examine retrospectively the contribution of 18Fluorodeoxyglucose positron emission tomography computed tomography (18FDG-PET/CT) to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer. AIM: To evaluate the response to Gemcitabine plus Cisplatin -based chemotherapy using 18FDG-PET/CT imaging in patients with metastatic bladder cancer. METHODS: Between July 2007 and April 2019, 79 patients underwent 18FDG-PET/CT imaging with the diagnosis of Metastatic Bladder Carcinoma (M-BCa). A total of 42 patients (38 male, 4 female) were included in the study, and all had been administered Gemcitabine plus Cisplatin-based chemotherapy. After completion of the therapy, the patients underwent a repeat 18FDG-PET/CT scan and the results were compared with the PET/CT findings before chemotherapy according to European Organisation for the Research and treatment of cancer criteria. Mean age was 66.1 years and standard deviation was 10.7 years (range: 41-84 years). RESULTS: Of the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent. CONCLUSION: 18FDG-PET/CT can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from PET/CT scans may be useful in the planning of secondline and thirdline chemotherapy.

2.
Mol Imaging Radionucl Ther ; 25(2): 85-90, 2016 Jun 05.
Article in English | MEDLINE | ID: mdl-27277325

ABSTRACT

OBJECTIVE: Differentiated thyroid cancers (DTC) are tumors with good prognosis. However, local recurrence or distant metastasis can be observed. In our study, we aimed to investigate the incidence of recurrence and the importance of diagnostic iodine-131 whole body scan (WBS) in clinical follow-up in patients with DTC. METHODS: The clinical data of 217 patients with DTC who were followed-up more than 3 years were reviewed retrospectively. The incidence of recurrence was investigated in a group of patients who had radioactive iodine (RAI) treatment and showed no sign of residual thyroid tissue or metastasis with diagnostic WBS that was performed at 6-12 months after therapy and had a thyroglobulin (Tg) level lower than 2 ng/dl. RESULTS: At the time of diagnosis, ten cases had thyroid capsule invasion, 25 cases had extra-thyroid soft tissue invasion, 11 patients showed lymph node metastasis and four patients had distant organ metastasis. One hundred forty-five patients had RAI treatment at ablation dose (75-100 mCi), whereas 35 patients had RAI treatment at metastasis dose (150-200 mCi). Thirty-seven patients with papillary microcarcinoma did not receive RAI treatment. In 12 (%7.5) of the 160 patients who were considered as "successful ablation", a recurrence was identified. Recurrence was detected by diagnostic WBS in all cases and stimulated Tg level was <2 ng/dL with the exception of the two cases who had distant metastasis. CONCLUSION: Identification of pathological findings with WBS in patients who developed local recurrence in the absence of elevated Tg highlights the importance of diagnostic WBS in clinical follow-up.

3.
Oncol Lett ; 11(1): 316-322, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26870210

ABSTRACT

The present study aimed to retrospectively review the contribution of 18F-fluorodeoxygluose-positron emission tomography/computed tomography (18F-FDG PET/CT) in the assessment of biochemical recurrence in patients with a diagnosis of local-stage prostate cancer (PCa) who underwent radical prostatectomy (RP) or received external beam radiation therapy (EBRT). A total of 28 patients who underwent RP or received EBRT for PCa between July 2007 and April 2013, and who underwent 18F-FDG PET/CT scanning for re-staging due to biochemical recurrence were included in the present study. The mean age of the patients was 65.07 years and the standard deviation was 7.51 years (range, 51-82 years). Of the 28 patients, 23 (82.1%) underwent RP and 5 (17.9%) received definitive EBRT. Prior to scanning, all patients were required to fast for 6 h, and ~1 h after the intravenous injection of 555 MBq 18F-FDG, whole-body PET scans were performed from the skull base to the upper thighs. Whole-body CT scans were performed in the craniocaudal direction. 18F-FDG PET images were reconstructed using CT data for attenuation correction. Histopathology examination or clinical follow-up was used to confirm any suspicious recurrent or metastatic lesions. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET/CT were 61.6, 75.0, 61.6, 75.0 and 71.4%, respectively. 18F-FDG PET/CT can detect local and distant metastases with a high accuracy in the assessment of biochemical recurrence, thus detecting occult metastases and allowing the re-staging of PCa in the patients receiving definitive treatment. It is considered that 18F-FDG PET/CT may be useful in re-assessing the patients with PCa receiving definitive treatment.

4.
J BUON ; 21(6): 1410-1418, 2016.
Article in English | MEDLINE | ID: mdl-28039701

ABSTRACT

PURPOSE: The purpose of this study was to analyse the association between the 18F-2-deoxy-2-fluorodeoxyglucose maximum standardized uptake value (SUVmax) of metastatic sites and molecular subtypes and survival in metastatic breast cancer (MBC) patients. METHODS: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) was performed in 176 MBC patients before any therapeutic intervention. The FDG uptakes of metastatic sites were evaluated using the SUVmax. Histopathological prognostic parameters, such as the tumor size, grade, lymph node involvement, lymphovascular invasion, estrogen (ER), progesterone receptors (PR), HER2 status and Ki67 were determined from the primary breast tumor tissue. The SUVmax of the metastatic sites was assessed in relation to the molecular subtypes and survival in univariate and multivariate analyses. Cox regression analysis was used to evaluate the associations between SUVmax measurements and overall survival (OS). RESULTS: The mean SUVmax of 176 tumors was 8.0. Among the subtypes 49 (28.8%) were luminal A, 51 (28.9%) luminal B, 35 (19.8%) HER2-overexpressing, and 41 (23.2%) triple- negative, and the corresponding means of SUVmax were 5.6, 7.4, 11.4, 11.0, respectively. A cut-off value of ≤8.4 yielded 80% sensitivity and 57.1% specificity with an area under the receiver operating characteristics curve (AUC) of 0.731 for predicting that a tumor was of the luminal A subtype. A cut-off value of SUVmax ≥10.05 yielded 62.9% sensitivity and 67.4% specificity with an AUC of 0.648 for predicting a HER2 overexpressing subtype. A cut-off value of SUVmax ≥9.25 yielded 61% sensitivity and 64.4% specificity with an AUC of 0.660 for predicting a triple-negative subtype. The SUVmax could not effectively differentiate patients with luminal B subtype. Cox regression analysis showed that in patients with MBC, a SUVmax ≤7.55 acted as an independent negative prognostic factor for OS (hazard ratio/HR = 1.552). CONCLUSION: The SUVmax of metastatic sites on pretreatment 18F-FDG PET/CT may be an independent prognostic factor for the diagnosis of molecular phenotypes and survival in MBC patients.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/diagnostic imaging , Fluorodeoxyglucose F18/pharmacokinetics , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals/pharmacokinetics , Adult , Aged , Area Under Curve , Biomarkers, Tumor/genetics , Biopsy , Breast Neoplasms/chemistry , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Female , Fluorodeoxyglucose F18/administration & dosage , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Middle Aged , Multivariate Analysis , Neoplasm Metastasis , Predictive Value of Tests , Prognosis , Proportional Hazards Models , ROC Curve , Radiopharmaceuticals/administration & dosage , Receptor, ErbB-2/genetics , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Retrospective Studies , Risk Factors , Time Factors , Tissue Distribution , Triple Negative Breast Neoplasms/chemistry , Triple Negative Breast Neoplasms/diagnostic imaging , Triple Negative Breast Neoplasms/mortality , Triple Negative Breast Neoplasms/pathology , Turkey
5.
J Phys Ther Sci ; 27(5): 1429-33, 2015 May.
Article in English | MEDLINE | ID: mdl-26157234

ABSTRACT

[Purpose] This prospective longitudinal study evaluated the changes in bone metabolism markers and bone mineral density of spinal cord injury patients over 3 years. We also assessed the relationships among the bone mineral density, bone metabolism, and clinical data of spinal cord injury patients. [Subjects and Methods] We assessed the clinical data (i.e., immobilization due to surgery, neurological status, neurological level, and extent of lesion) in 20 spinal cord injury patients. Bone mineral density, and hormonal and biochemical markers of the patients were measured at 0, 6, 12, and 36 months. [Results] Femoral neck T score decreased significantly at 36 months (p < 0.05). Among the hormonal markers, parathyroid hormone and vitamin D were significantly elevated, while bone turnover markers (i.e., deoxypyridinoline and osteocalcin) were significantly decreased at 12 and 36 months (p < 0.05). [Conclusion] Bone mineral density of the femoral neck decreases significantly during the long-term follow-up of patients with spinal cord injury due to osteoporosis. This could be due to changes in hormonal and bone turnover markers.

6.
Exp Ther Med ; 9(3): 717-724, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25667618

ABSTRACT

The aim of the present study was to retrospectively evaluate the contribution and effectiveness of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) scans in the restaging of patients following radical cystectomy due to muscle-invasive bladder carcinoma (MIBC). A total of 51 patients (45 males and six females) who underwent radical cystectomy due to invasive bladder cancer, and had an 18F-FDG-PET/CT scan for restaging between July 2007 and April 2013, were included in the present study. The mean age was 62.3±9.79 years (range, 40-82 years). Patients underwent a six-hour fast prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed ~1 h after the intravenous injection of 555 MBq 18F-FDG. Whole-body CT scanning was performed in a cranio-caudal direction. 18F-FDG-PET images were reconstructed using CT data for attenuation correction. Histopathology or clinical follow-up was used to confirm any suspicious recurrent or metastatic lesions. The results for sensitivity, specificity, positive predictive value (PPV), negative predictive value and accuracy of 18F-FDG-PET/CT were 92, 83, 94, 77 and 90%, respectively. In conclusion, 18F-FDG-PET/CT efficiently detects local recurrence and distant metastases with high sensitivity and PPV in the restaging of patients who underwent radical cystectomy due to invasive bladder cancer. This procedure could play an important role in rendering decisions regarding radiotherapy or chemotherapy and post-operative follow-up, and could influence the entire decision-making process.

7.
Urologia ; 82(2): 114-7, 2015.
Article in English | MEDLINE | ID: mdl-25451879

ABSTRACT

BACKGROUND: The adrenal glands are among the target metastatic organs due to the potential of systemic metastasis from renal cell carcinoma (RCC). The number of cases with bilateral metachronous metastases from RCC is about twenty. PATIENTS AND METHODS: A sixty-one-year-old man presented for routine checks due to an operated left renal tumor (clear cell carcinoma, PT2N0M0, Fuhrman grade III). The patient underwent 18FDG-PET/CT in order to re-stage the disease upon observation of bilateral adrenal masses on ultrasound and CT. A bilateral metachronous metastasis was found, whose SUVmax was 6.7 x 50 x 38 x 20 cm on the left adrenal gland, and another metastasis whose SUVmax was 5.5 40 x 29 x 20 on the right adrenal gland. RESULTS: The patient underwent a CT-guided biopsy and diagnosis of adrenal metastasis was made by pathological and immunohistochemical examination. The laparoscopic treatment was performed. CONCLUSIONS: There is no standard approach for the treatment of these patients in the literature. But metastasectomy is the most realistic part of the treatment. Making definitive diagnosis with biopsy, following hormonal examination and treatment with minimally invasive adrenal sparing surgical procedure containing frozen-section are strongly recommended. Cancer specific survival significantly increases with metastasectomy.


Subject(s)
Adrenal Gland Neoplasms/secondary , Adrenal Gland Neoplasms/surgery , Adrenalectomy , Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/surgery , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Neoplasms, Second Primary/surgery , Adrenal Gland Neoplasms/diagnostic imaging , Adrenalectomy/methods , Carcinoma, Renal Cell/diagnostic imaging , Fluorodeoxyglucose F18/pharmacology , Humans , Image-Guided Biopsy , Kidney Neoplasms/diagnostic imaging , Male , Middle Aged , Neoplasms, Second Primary/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Radiography, Interventional , Radiopharmaceuticals/pharmacology , Tomography, X-Ray Computed/methods , Treatment Outcome
8.
Mol Imaging Radionucl Ther ; 22(1): 18-20, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23610727

ABSTRACT

UNLABELLED: We report a case with Non-Hodgkin Lymphoma with a focus of intense hypermetabolism in the sellar region in the primary staging and posttreatment whole body F-18 FDG PET. Further evaluation with magnetic resonance imaging after posttreatment FDG PET revealed a pituitary adenoma. Endocrinologic workup was normal consistent with nonfunctioning pituitary adenoma and endocrinologists decided to follow up the patient by yearly magnetic resonance imaging. This case demonstrates a nonfunctioning pituitary adenoma by whole body FDG PET and emphasizes the importance of pursuing incidental findings detected in the sella on PET imaging. CONFLICT OF INTEREST: None declared.

9.
Mol Imaging Radionucl Ther ; 21(2): 63-8, 2012 Aug.
Article in English | MEDLINE | ID: mdl-23487242

ABSTRACT

OBJECTIVE: Because the detection of the primary tumour is of importance to optimize the patient's management and allows a targeted therapy, the performance of hybrid positron emission tomography-computed tomography (PET/CT) using fluorodeoxyglucose (FDG) in the detection of primary tumors and unrecognized metastases with cervical lymph node metastases were evaluated in a retrospective study. MATERIAL AND METHODS: Twenty patients with cervical lymph node metastases of unknown primary tumors underwent staging with FDG-PET/CT. All underwent head and neck examinations, computed tomography (CT), and/or magnetic resonance imaging (MRI), panendoscopies, and biopsies of head and neck mucosal sites. The diagnostic accuracy of FDG-PET/CT in detecting primary tumors was compared with that of histopathology and clinical follow-up. The ability of FDG-PET/CT to detect distant metastases was also tested. RESULTS: PET/CT was positive with an increased FDG uptake suggesting the potential primary site in 45% of patients (9/20). PET/CT findings were true positive in 7, true negative in 10, false positive in 2, and false negative in 1 patients, resulting in a sensitivity of 87%, a specificity of 83%, an accuracy of 85%, a positive predictive value of 77% and a negative predictive value of 90%. Also, PET/CT showed distant metastases in seven patients. CONCLUSION: FDG-PET/CT can be successfully used for the identification of the primary site and distant metastases in patients with cervical lymph node metastases from an unknown primary cancer. CONFLICT OF INTEREST: None declared.

15.
Ann Nucl Med ; 20(4): 269-75, 2006 May.
Article in English | MEDLINE | ID: mdl-16856570

ABSTRACT

PURPOSE: The purpose of this study was to evaluate whether the degree of technetium-99m methoxyisobutylisonitrile (MIBI) uptake and its retention in delayed imaging in small cell lung cancer (SCLC) was correlated with the response to multiagent chemotherapy and to investigate if there was a relationship between the survival time of patients with SCLC and Tc-99m MIBI SPECT tumor uptake parameters at the time of diagnosis. METHODS: Between 1998 and by December 2004, 40 patients with SCLC were studied with Tc-99m MIBI SPECT at the time of diagnosis. The patients were classified by a follow-up CT as good responders (complete or partial remission) and poor responders (stable disease or progressive disease). Following i.v. administration of 740 MBq Tc-99m MIBI, SPECT imaging at 30 minutes (early) and 2 hours (delayed) was performed. Regions of interests were placed over the tumors and contralateral normal lung tissue on one transverse section. The uptake ratio of the lesion to that in the contralateral normal lung was obtained from early images (early ratio; ER) as well as delayed images (delayed ratio; DR). The retention index (RI%) was measured as: RI% = [(DR-ER)/ER] x 100. Tc-99m MIBI tumor uptake parameters were compared with chemotherapeutic response and survival time. RESULTS: Of 40 patients, 29 patients were good responders (72.5%) and 11 patients were poor responders (27.5%). RI% of Tc-99m MIBI SPECT in the group of good response was significantly higher than in that with poor response (p < 0.05). On the other hand, there was no significant difference between the two groups with respect to ER or DR values. Four of 40 patients were still alive with disease (10%). The patient survival time varied from 1 to 70 months (mean survival time = 12.9 +/- 13.4 months). There was no significant difference between the survival time of patients with respect to ER or DR of Tc-99m MIBI SPECT imaging. When median RI% was accepted as a cut-off value (-3.85%), patients with higher RI% values had a longer survival time (12 months) when compared with those with low RI% (8 months), p < 0.05. CONCLUSION: Our results suggest that Tc-99m MIBI SPECT could accurately predict the chemotherapy response in patients with SCLC. RI% of Tc-99m MIBI SPECT is recommended to differentiate patients with a poor response to chemotherapy and good responders, and RI% of Tc-99m MIBI SPECT appears as the only parameter that may be useful in predicting the survival of patients with SCLC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Small Cell/diagnostic imaging , Carcinoma, Small Cell/drug therapy , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Technetium Tc 99m Sestamibi , Adult , Aged , Carcinoma, Small Cell/metabolism , Carcinoma, Small Cell/mortality , Cisplatin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/mortality , Male , Middle Aged , Outcome Assessment, Health Care/methods , Prognosis , Radiopharmaceuticals/pharmacokinetics , Reproducibility of Results , Sensitivity and Specificity , Survival Analysis , Survival Rate , Technetium Tc 99m Sestamibi/pharmacokinetics , Tomography, Emission-Computed, Single-Photon/statistics & numerical data , Treatment Outcome , Turkey/epidemiology
16.
J Endocrinol ; 190(1): 151-6, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16837619

ABSTRACT

The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 microg/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40.1 +/- 13.3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH 0.05). TPOAb titers increased significantly in group S21 (38.1%, P < 0.01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5.2%, P < 0.01). L-selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 microg/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time.


Subject(s)
Selenium/administration & dosage , Thyroiditis, Autoimmune/drug therapy , Adult , Analysis of Variance , Antibodies, Monoclonal/blood , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Iodide Peroxidase/immunology , Male , Middle Aged , Selenium/therapeutic use , Statistics, Nonparametric , Thyroiditis, Autoimmune/blood , Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...